{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T02:53:23Z","timestamp":1794020003046,"version":"4.8.0"},"reference-count":33,"publisher":"BMJ","issue":"6","license":[{"start":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T00:00:00Z","timestamp":1772150400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001826","name":"ZonMw","doi-asserted-by":"publisher","award":["848016011"],"award-info":[{"award-number":["848016011"]}],"id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004243","name":"Prinses Beatrix Spierfonds","doi-asserted-by":"publisher","award":["W.OR17-03"],"award-info":[{"award-number":["W.OR17-03"]}],"id":[{"id":"10.13039\/501100004243","id-type":"DOI","asserted-by":"publisher"}]},{"name":"GAIN UK","award":["NA"],"award-info":[{"award-number":["NA"]}]},{"DOI":"10.13039\/100013560","name":"GBS\/CIDP Foundation International","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/100013560","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Neurol Neurosurg Psychiatry"],"accepted":{"date-parts":[[2026,2,9]]},"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Most patients with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) require maintenance treatment. We aimed to determine whether combined treatment with intravenous immunoglobulin (IVIg) and intravenous methylprednisolone (IVMP) increases remission rates compared with IVIg and placebo.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We performed a randomised, double-blind, placebo-controlled study. Adults with CIDP who were treatment naive, relapsed after a remission or required continued treatment after a single IVIg dose were included. Participants were treated with IVMP (1000 mg) or placebo (sodium chloride) every 3\u2009weeks for 18 weeks. All participants received IVIg treatment consisting of a loading dose (2 g\/kg) and serial maintenance treatments (1 g\/kg). The primary outcome was remission, defined as sustained improvement on disability scales at 52 weeks without need for further treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Enrolment was halted after the inclusion of 77 of the 96 planned participants because of safety concerns: four thromboembolic events occurred in the IVIg\/IVMP group compared with none in the IVIg\/placebo group. 14 of 37 (38%) participants in the IVIg\/IVMP group were in remission at 52 weeks compared with 11 out of 40 (28%) in the IVIg\/placebo group, with a difference of 10% (95% CI \u221211 to 31; p=0.47). Several secondary outcomes showed a greater magnitude of improvement in disability and impairment at 18 and 52 weeks in the IVIg\/IVMP group.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The study was prematurely stopped due to safety concerns after four thromboembolic events in the IVIg plus IVMP group. Combined treatment did not lead to significantly more frequent remissions than IVIg alone in the doses used in this study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"isrctn\" xlink:href=\"ISRCTN15893334\">ISRCTN15893334<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jnnp-2025-338140","type":"journal-article","created":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T18:20:22Z","timestamp":1772216422000},"page":"558-566","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":7,"title":["Intravenous methylprednisolone as add-on induction therapy for chronic inflammatory demyelinating polyradiculoneuropathy: a randomised controlled trial"],"prefix":"10.1136","volume":"97","clinical-trial-number":[{"clinical-trial-number":"isrctn15893334","registry":"10.18810\/isrctn"},{"clinical-trial-number":"isrctn15893334","registry":"10.18810\/isrctn"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4446-1362","authenticated-orcid":false,"given":"Sander R M","family":"Bus","sequence":"first","affiliation":[{"name":"Department of Neurology, Amsterdam UMC Location AMC, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5336-712X","authenticated-orcid":false,"given":"Iris N","family":"van Doorn","sequence":"additional","affiliation":[{"name":"Department of Neurology, Amsterdam UMC Location AMC, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0257-8362","authenticated-orcid":false,"given":"Laura","family":"Zambreanu","sequence":"additional","affiliation":[{"name":"Centre for Neuromuscular Disease, University College London Hospitals NHS Foundation Trust, National Hospital for Neurology and Neurosurgery, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2522-4081","authenticated-orcid":false,"given":"Luuk","family":"Wieske","sequence":"additional","affiliation":[{"name":"Department of Neurology, Amsterdam UMC Location AMC, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes A","family":"Bogaards","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Data Science, Amsterdam UMC Location AMC, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Abbas","sequence":"additional","affiliation":[{"name":"Regional Neuromuscular Service, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuf A","family":"Rajabally","sequence":"additional","affiliation":[{"name":"Department of Neurology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander F J E","family":"Vrancken","sequence":"additional","affiliation":[{"name":"Department of Neurology, University Medical Centre Utrecht Brain Centre, Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pieter A","family":"van Doorn","sequence":"additional","affiliation":[{"name":"Department of Neurology, Erasmus MC University Medical Center Rotterdam, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9702-0256","authenticated-orcid":false,"given":"Robert D M","family":"Hadden","sequence":"additional","affiliation":[{"name":"Department of Neurology, King\u2019s College Hospital, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camiel","family":"Verhamme","sequence":"additional","affiliation":[{"name":"Department of Neurology, Amsterdam UMC Location AMC, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rob J","family":"de Haan","sequence":"additional","affiliation":[{"name":"Clinical Research Unit, Amsterdam UMC Location AMC, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corianne A J M","family":"de Borgie","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Data Science, Amsterdam UMC Location AMC, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivo N","family":"van Schaik","sequence":"additional","affiliation":[{"name":"Sanquin Blood Supply Foundation, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3174-6027","authenticated-orcid":false,"given":"Michael P","family":"Lunn","sequence":"additional","affiliation":[{"name":"Centre for Neuromuscular Disease, University College London Hospitals NHS Foundation Trust, National Hospital for Neurology and Neurosurgery, London, UK"},{"name":"NIHR Biomedical Research Centre, University College London Hospitals NHS Foundation Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filip","family":"Eftimov","sequence":"additional","affiliation":[{"name":"Department of Neurology, Amsterdam UMC Location AMC, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,2,27]]},"reference":[{"key":"2026051402050522000_97.6.558.1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2018-318714"},{"key":"2026051402050522000_97.6.558.2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.66.5.677"},{"key":"2026051402050522000_97.6.558.3","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2014-309697"},{"key":"2026051402050522000_97.6.558.4","doi-asserted-by":"publisher","DOI":"10.1111\/ene.14959"},{"key":"2026051402050522000_97.6.558.5","article-title":"Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy","volume":"2024","author":"Bus","year":"2024","journal-title":"Cochrane Database Syst Rev"},{"key":"2026051402050522000_97.6.558.6","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1007\/s00415-018-8948-y","article-title":"Corticosteroids in chronic inflammatory demyelinating polyneuropathy\u202f: A retrospective, multicentre study, comparing efficacy and safety of daily prednisolone, pulsed dexamethasone, and pulsed intravenous methylprednisolone","volume":"265","author":"van Lieverloo","year":"2018","journal-title":"J Neurol"},{"key":"2026051402050522000_97.6.558.7","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(10)70021-1"},{"key":"2026051402050522000_97.6.558.8","article-title":"Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy","volume":"12","author":"Eftimov","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"2026051402050522000_97.6.558.9","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1093\/brain\/awac054","article-title":"Withdrawal of intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy","volume":"145","author":"Adrichem","year":"2022","journal-title":"Brain (Bacau)"},{"key":"2026051402050522000_97.6.558.10","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(10)70041-7"},{"key":"2026051402050522000_97.6.558.11","doi-asserted-by":"publisher","DOI":"10.1111\/j.1085-9489.2005.0010203.x"},{"key":"2026051402050522000_97.6.558.12","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.1991.00530140113024"},{"key":"2026051402050522000_97.6.558.13","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e31824e8f84"},{"key":"2026051402050522000_97.6.558.14","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1111\/ene.14096","article-title":"Combined intravenous immunoglobulin and methylprednisolone as induction treatment in chronic inflammatory demyelinating polyneuropathy (OPTIC protocol): a prospective pilot study","volume":"27","author":"Adrichem","year":"2020","journal-title":"Euro J of Neurology"},{"key":"2026051402050522000_97.6.558.15","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1331.2009.02930.x"},{"key":"2026051402050522000_97.6.558.16","doi-asserted-by":"crossref","DOI":"10.1186\/s13063-021-05083-1","article-title":"Intravenous immunoglobulin and intravenous methylprednisolone as optimal induction treatment in chronic inflammatory demyelinating polyradiculoneuropathy: protocol of an international, randomised, double-blind, placebo-controlled trial (OPTIC)","volume":"22","author":"Bus","year":"2021","journal-title":"Trials"},{"key":"2026051402050522000_97.6.558.17","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(07)70329-0"},{"key":"2026051402050522000_97.6.558.18","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1212\/WNL.0b013e318208824b","article-title":"Rasch-built Overall Disability Scale (R-ODS) for immune-mediated peripheral neuropathies","volume":"76","author":"van Nes","year":"2011","journal-title":"Neurology (ECronicon)"},{"key":"2026051402050522000_97.6.558.19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2117912"},{"key":"2026051402050522000_97.6.558.20","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(12)70093-5"},{"key":"2026051402050522000_97.6.558.21","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1093\/brain\/awab422","article-title":"Randomized trial of three IVIg doses for treating chronic inflammatory demyelinating polyneuropathy","volume":"145","author":"Cornblath","year":"2022","journal-title":"Brain (Bacau)"},{"key":"2026051402050522000_97.6.558.22","first-page":"e635","article-title":"Thromboembolic risk with IVIg: Incidence and risk factors in patients with inflammatory neuropathy","volume":"94","author":"Kapoor","year":"2020","journal-title":"Neurology (ECronicon)"},{"key":"2026051402050522000_97.6.558.23","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2022-328881"},{"key":"2026051402050522000_97.6.558.24","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.167.9.935"},{"key":"2026051402050522000_97.6.558.25","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1001\/jamainternmed.2013.122","article-title":"Use of glucocorticoids and risk of venous thromboembolism: a nationwide population-based case-control study","volume":"173","author":"Johannesdottir","year":"2013","journal-title":"JAMA Intern Med"},{"key":"2026051402050522000_97.6.558.26","first-page":"e671","article-title":"Randomized Double-Blind Placebo-Controlled Trial of the Corticosteroid-Sparing Effects of Immunoglobulin in Myasthenia Gravis","volume":"100","author":"Bril","year":"2023","journal-title":"Neurology (ECronicon)"},{"key":"2026051402050522000_97.6.558.27","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)15324-X"},{"key":"2026051402050522000_97.6.558.28","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)61930-2"},{"key":"2026051402050522000_97.6.558.29","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.j2099","article-title":"Development and validation of QRISK3 risk prediction algorithms to estimate future risk of cardiovascular disease: prospective cohort study","volume":"357","author":"Hippisley-Cox","year":"2017","journal-title":"BMJ"},{"key":"2026051402050522000_97.6.558.30","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.d4656","article-title":"Development and validation of risk prediction algorithm (QThrombosis) to estimate future risk of venous thromboembolism: prospective cohort study","volume":"343","author":"Hippisley-Cox","year":"2011","journal-title":"BMJ"},{"key":"2026051402050522000_97.6.558.31","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/nrneurol.2017.84","article-title":"Autoantibodies in chronic inflammatory neuropathies: diagnostic and therapeutic implications","volume":"13","author":"Querol","year":"2017","journal-title":"Nat Rev Neurol"},{"key":"2026051402050522000_97.6.558.32","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dym020"},{"key":"2026051402050522000_97.6.558.33","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dym088"}],"container-title":["Journal of Neurology, Neurosurgery &amp; Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jnnp-2025-338140","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T09:06:07Z","timestamp":1778749567000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnnp.bmj.com\/lookup\/doi\/10.1136\/jnnp-2025-338140"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,27]]},"references-count":33,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,5,14]]},"published-print":{"date-parts":[[2026,6]]}},"alternative-id":["10.1136\/jnnp-2025-338140"],"URL":"https:\/\/doi.org\/10.1136\/jnnp-2025-338140","relation":{},"ISSN":["0022-3050","1468-330X"],"issn-type":[{"value":"0022-3050","type":"print"},{"value":"1468-330X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,27]]}}}